Evidence map›Paper›PMID 40164133›Full record

ArticleEndoscopy2025

Effect of proton pump inhibitors on occlusion of lumen-apposing metal stents and rate of endoscopic necrosectomies: a Europe-wide multicenter cohort study.

Jacob Hamm, Alzbeta Busana, Ahmad Amanzada, Alexander Arlt, Thomas Asendorf, Samantha Carswell, Ulrike Denzer, Louis Elsing, Fabian Frost, Lucia Guilabert and 15 more

Abstract readMulticenter Study
In one paragraph

Article in Endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Jacob HammDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, Goettingen, Germany.
Alzbeta BusanaDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, Goettingen, Germany.
Ahmad AmanzadaDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, Goettingen, Germany.
Alexander ArltDepartment of Gastroenterology, University Hospital Oldenburg, Oldenburg, Germany.
Thomas AsendorfDepartment of Medical Statistics, University Medical Center Goettingen, Goettingen, Germany.
Samantha CarswellHPB and Transplant Unit, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.
Ulrike DenzerDepartment of Gastroenterology, University Hospital Marburg, Marburg, Germany.
Louis ElsingDepartment of Oncology, Gastroenterology, Hepatology and Pneumology, University Hospital Leipzig, Leipzig, Germany.
Fabian FrostDepartment of Medicine A, University Medicine Greifswald, Greifswald, Germany.
Lucia GuilabertDepartment of Gastroenterology, Hospital General Universitario Dr. Balmis, ISABIAL (Instituto de Investigación Sanitaria y Biomédica de Alicante), Alicante, Spain.ORCID 0000-0002-9597-6377
Karim HameschMedical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany.ORCID 0000-0002-1702-2746
Marcus HollenbachDepartment of Gastroenterology, University Hospital Marburg, Marburg, Germany.
Péter HegyiTranslational Pancreatology Research Group, Interdisciplinary Center of Excellence for Research Development and Innovation, University of Szeged, Szeged, Hungary.
Alexander KlegerInstitute of Molecular Oncology and Stem Cell Biology, University Hospital Ulm, Ulm, Germany.
Jan Krivinka2nd Department of Internal Medicine - Gastroenterology and Geriatrics, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
Lumir Kunovsky2nd Department of Internal Medicine - Gastroenterology and Geriatrics, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.ORCID 0000-0003-2985-8759
Christian MeinhardtDepartment of Gastroenterology, University Hospital Oldenburg, Oldenburg, Germany.
Veit PhillipDepartment of Clinical Medicine II, Technical University of Munich, TUM School of Medicine and Health, TUM University Hospital, Munich, Germany.
Sophie Schlosser-HupfDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious diseases, University Hospital Regensburg, Regensburg, Bavaria, Germany.
Simon SirtlDepartment of Medicine II, University Hospital LMU Munich, Munich, Germany.ORCID 0000-0002-6047-334X
Lukas WelschDepartment of Gastroenterology, Diabetology and Infectiology, Klinikum Hanau, Hanau, Germany.
Julian Cardinal von WiddernDepartment of Internal Medicine I, Martin Luther University Halle-Wittenberg, Halle, Germany.
Albrecht NeesseDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, Goettingen, Germany.
Christoph Ammer-HerrmenauDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, Goettingen, Germany.ORCID 0009-0009-2465-8927
PROTOCOL working group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLumen-apposing metal stents (LAMS) are widely used to drain walled-off necrosis (WON). LAMS occlusion is a significant clinical problem and identification of risk factors for LAMS occlusion could contribute to novel preventive strategies. A previous study suggested contradictory effects of proton pump inhibitors (PPIs) on occlusion and necrosectomy rates.

methodsWe conducted a Europe-wide multicenter retrospective cohort study assessing WONs drained by LAMS. The primary aims were to assess the strength of association between PPI intake and LAMS occlusion and necrosectomy rates, respectively. The secondary aim was to assess the strength of association between PPI intake and other LAMS-associated complications. Multiple mixed-effects models were used to control for possible confounding covariates.

results893 patients with 967 LAMS from 17 centers were included. After excluding incomplete datasets and patients who took PPIs intermittently, 768 LAMS remained. The overall occlusion rate was 28.0 %. Most occlusions occurred within 10 days. Most patients received PPIs continuously (n = 577 vs. no intake n = 191). In patients who did not use PPIs continuously, lower rates of LAMS occlusion (odds ratio [OR] 0.61,

conclusionPPI intake was associated with higher rates of LAMS occlusion and necrosectomy.

Indexed as

DrainagePancreatitis, Acute NecrotizingProton Pump InhibitorsStentsAgedEuropeFemaleHumansMaleMiddle AgedNecrosisRetrospective StudiesRisk FactorsProton Pump Inhibitors

Identifiers

PMID40164133
PMCPMC12307040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.